Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Telavancin regulatory update

Theravance said it was notified by FDA that the agency's Anti-Infective Drugs Advisory Committee "may soon meet" to review an NDA

Read the full 211 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE